BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

MLA

Meeks, Huong D., et al. “BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.” Journal of the National Cancer Institute, vol. 108, no. 2, Nov. 2015. EBSCOhost, https://doi.org/10.1093/jnci/djv315.

APA

Meeks, H. D., Song, H., Michailidou, K., Bolla, M. K., Dennis, J., Wang, Q., Barrowdale, D., Frost, D., McGuffog, L., Ellis, S., Feng, B., Buys, S. S., Hopper, J. L., Southey, M. C., Tesoriero, A., James, P. A., Bruinsma, F., Campbell, I. G., Broeks, A., … Goldgar, D. E. (2015). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 108(2). https://doi.org/10.1093/jnci/djv315

Chicago

Meeks, Huong D, Honglin Song, Kyriaki Michailidou, Manjeet K Bolla, Joe Dennis, Qin Wang, Daniel Barrowdale, et al. 2015. “BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.” Journal of the National Cancer Institute 108 (2). doi:10.1093/jnci/djv315.